NovaBridge (NBP) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$37.9M

Net income growth (year over year)

−337.58%

Net margin

—

Return on equity

−37.95%

EPS (trailing twelve months)

−$0.69

Book value per share

$1.73

P/E (trailing twelve months)

—

Price to book

0.75

Debt to assets

13.15%

Payout ratio

—

Dividend yield

—

Company profile

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

• How do I buy stock in NovaBridge (NBP)?

  NBP trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.